| 1 |
Details of business |
https://www.aartipharmalabs.com/products-and-services |
| 2 |
Terms and conditions of Appointment of Independent Directors |
https://www.aartipharmalabs.com/investors/terms-and-conditions-of-appointment-of-independent-director.pdf |
| 3 |
Composition of Committees of Board of Directors |
https://www.aartipharmalabs.com/investors/composition-of-committees.pdf |
| 4 |
Code of Conduct |
https://www.aartipharmalabs.com/investors/code-of-conduct-feb-2023.pdf |
| 5 |
Vigil mechanism/ Whistle Blower policy |
https://www.aartipharmalabs.com/investors/vigil-mechanism-policy-feb-2023.pdf |
| 6 |
Criteria for making payment to Non Executive Directors |
https://www.aartipharmalabs.com/investors/nomination-and-remuneration-policy-feb-2023.pdf |
| 7 |
Policy on Related Party Transactions |
https://www.aartipharmalabs.com/investors/apl-rpt-policy-revised-feb-2025-final.pdf |
| 8 |
Policy for determining Material Subsidiaries |
https://www.aartipharmalabs.com/investors/policy-on-determination-of-material-subsidiary-feb-2023.pdf |
| 9 |
Familiarization programmes imparted to Independent Directors |
https://www.aartipharmalabs.com/regarding-independent-directors |
| 10 |
Contact details for Grievance Redressal |
https://www.aartipharmalabs.com/investors-relations |
| 11 |
Financial Information |
https://www.aartipharmalabs.com/quarterly-results |
| 12 |
Shareholding Pattern |
https://www.aartipharmalabs.com/shareholding-pattern |
| 13 |
Details of analysts or institutional investors meet |
No analysts or institutional investors meet were conducted nor any presentations were made to analysts or institutional investors. |
|
| 14 |
Disclosures under Regulation 47(1) of LODR |
https://www.aartipharmalabs.com/newspaper-advertisement |
| 15 |
Credit Rating |
https://www.aartipharmalabs.com/credit-ratings |
| 16 |
Subsidiary Financial Statements |
https://www.aartipharmalabs.com/subsidiary-companies-balance-sheets |
| 17 |
Secretarial Compliance Report |
https://www.aartipharmalabs.com/annual-secretarial-compliance-report |
| 18 |
Materiality Policy |
https://www.aartipharmalabs.com/investors/policy-on-materiality-of-events-feb-2023.pdf |
| 19 |
Contact details of KMP for determining materiality |
https://www.aartipharmalabs.com/investors-relations |
| 20 |
Disclosures under Regulation 30(8) of SEBI
(LODR) Regulations, 2015 |
https://www.aartipharmalabs.com/material-and-recent-news |
| 21 |
Dividend Distribution Policy |
https://www.aartipharmalabs.com/investors/dividend-distribution-policy-feb-2023.pdf |
| 22 |
Annual Return |
https://www.aartipharmalabs.com/annual-return |
